Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

INDUCTION OF HEPATIC PHASE II DRUG-METABOLIZING ENZYMES BY 1,7-PHENANTHROLINE IN RATS IS ACCOMPANIED BY INDUCTION OF MRP3

Sui Wang, Dylan P. Hartley, Suzanne L. Ciccotto, Stella H. Vincent, Ronald B. Franklin and Mi-Sook Kim
Drug Metabolism and Disposition June 2003, 31 (6) 773-775; DOI: https://doi.org/10.1124/dmd.31.6.773
Sui Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dylan P. Hartley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne L. Ciccotto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stella H. Vincent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald B. Franklin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mi-Sook Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The purpose of the present study was to evaluate the effect of 1,7-phenanthroline (PH), which has been proposed to be a selective phase II enzyme inducer, on the gene expression of xenobiotic transporters, as well as hepatic and renal drug-metabolizing enzymes. After oral administration of PH for 3 days to male Sprague-Dawley rats, mRNA levels in liver (75 and 150 mg/kg doses) and kidney (75 mg/kg dose only) were determined using real-time quantitative polymerase chain reaction. At 150 mg/kg/day, PH treatment resulted in significant increases in hepatic mRNA levels of Mrp3 (36-fold), UGT1A6 (20-fold), UGT2B1 (4-fold), and quinone reductase (QR, 5-fold), compared with the vehicle-treated group. Similar increases in Mrp3 (99-fold), UGT1A6 (17-fold), UGT2B1 (3-fold), and QR (11-fold) mRNA levels were observed in the liver after PH treatment of rats at 75 mg/kg/day. In contrast, the expression levels of CYP2C11 and Oatp2 were decreased by ∼80 and 50%, respectively. In addition, PH (75 mg/kg/day) elicited statistically significant changes in renal gene expression of CYP3A1, UGT1A6, QR, and Mrp3, but the magnitude of renal Mrp3 induction was less than 2-fold over control. Although PH is known to modulate hepatic glucuronidation in vivo, these data indicated that PH induced mRNA levels of the efflux transporter, Mrp3, which may also affect the disposition of xenobiotics.

Multidrug resistance proteins 1, 2, and 3 (Mrp1,1 2, and 3) have gained significance during the last few years because of their function as transporters of organic anions and conjugates, and their involvement in hepatic detoxification and tissue-specific distribution of drugs (Konig et al., 1999; Hirohashi et al., 1999; Borst et al., 2000). Notably, induction of hepatic rat Mrp3 and another transporter, Oatp2, by drugs like phenobarbital was implicated in the altered disposition of acetaminophen and the enhanced uptake of digoxin in rats (Rausch-Derra et al., 2001; Xiong et al., 2002a). Mrp3 induction has been shown also with oltipraz (Cherrington et al., 2002), a dithiolthione phase II enzyme inducer being investigated as a chemoprotectant against aflatoxin carcinogenicity and hepatotoxicity (Kwak et al., 2001a). Oltipraz and other selective phase II inducers, such as 1,7-phenanthroline (PH), offer a new mechanism of protection against carcinogenic and hepatotoxic compounds by inducing the enzymes involved in their metabolism [glutathione S-transferase (GST) and UDP-glucuronosyltransferase (UGT)], without increasing cytochrome P450-mediated bioactivation (Franklin and Moody, 1992; Franklin et al., 1993; Buetler et al., 1995; Vargas et al., 1998; Dong et al., 1999; Lamb and Franklin, 2000). Additionally, selective phase II inducers can be used to modulate in vivo exposure to acyl glucuronides. In this regard, a significant increase in the glucuronidation of benoxaprofen, a nonsteroidal anti-inflammatory drug, was observed when rats were treated with PH at 75 mg/kg/day for 3 days, resulting in a 2-fold increase in the biliary excretion of the acyl glucuronide, and an 8-fold increase in the peak plasma concentration (Cmax) and area under the curve values of the acyl glucuronide (Dong et al., 1999).

In the present study, we report that PH significantly induced not only mRNA levels of hepatic phase II enzymes, but also mRNA levels of Mrp3, which is likely to contribute to the altered metabolism and disposition of xenobiotics and their metabolites in PH-treated rats.

Materials and Methods

Materials. PH was purchased from Sigma-Aldrich (St. Louis, MO). The purity, verified by high-pressure liquid chromatography, was 99.5%. Solvents used for analysis were of analytical or high-pressure liquid chromatography grade (Fisher Scientific, Pittsburgh, PA).

In Vivo Animal Studies. All studies were reviewed and approved by the Merck Research Laboratories Institutional Animal Care and Use Committee. Male Sprague-Dawley rats were obtained from Charles River Laboratories Inc. (Wilmington, MA). After an overnight fast, five male Sprague-Dawley rats were dosed orally with PH at 150 mg/kg once daily for 3 days, and four male Sprague-Dawley rats were dosed with vehicle (0.1 M citric acid in 0.5% methylcellulose) in the same manner. Livers were removed from treated and vehicle control rats at 24 h after the last dose and stored at -70°C for quantitation of mRNA. In a separate experiment, three rats were dosed with PH at 75 mg/kg/day for 3 days, and an additional three rats were dosed with vehicle in the same manner. At 24 h after the last dose, the livers and kidneys were removed and stored at -70°C for mRNA quantification.

Development of Specific Primers and Probes for Quantitative Real-Time Polymerase Chain Reaction. Coding sequences for the genes listed in Table 1 were accessed from GenBank. Specific target regions within the coding sequences were determined through nucleotide sequence alignment comparisons of targets within multiple member gene families (e.g., Oatp2 with Oatps, Mrp2 with Mrps, CYP2C11 with CYP2C12, etc.). Primers and probes were designed to the selected target using Applied Biosystems Inc. (Foster City, CA) Primer Express software (v.2.0). All primers and probes were submitted to the National Center for Biotechnological Information for nucleotide comparison using the basic logarithmic alignment search tool (BLASTn) search for short, nearly exact sequences to ensure specificity. Primers and probes were synthesized by QIAGEN Operon (Alameda, CA), where primers were 5′- and 3′-labeled with the 6-carboxyfluorescein and 6-carboxytetram-ethylrhodamine reporter dyes, respectively. The rodent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primer/probe set was purchased from Applied Biosystems Inc. and used per manufacturer's instructions. Each RNA sample was reverse-transcribed before analysis of different gene expression by PCR. Real-time quantitative PCR was performed using an ABI PRISM 7700 Sequence Detector instrument and Sequence Detector v.1.7 software (PerkinElmer Instruments, Skelton, CT).

View this table:
  • View inline
  • View popup
TABLE 1

Rat primer-probe sets and gene abbreviations

mRNA Isolation and Quantitative Real-Time Polymerase Chain Reaction. Total RNA from rat tissues was isolated using the SV Total RNA Isolation System (Promega, Madison, WI) according to the manufacturer's instructions. Samples were quantitated by spectrophotometry and diluted to a concentration of 15 ng/μl. Aliquots (500 ng) of RNA were analyzed by agarose/formaldehyde gel electrophoresis to check RNA integrity. Samples were then assayed in triplicate 25-μl reactions using 25 ng of RNA per reaction. Gene-specific primers were used at 7.5 pmol per reaction, and the gene-specific probes were used at 5 pmol per reaction. GAPDH was used to normalize gene expression in all samples since it is a highly expressed gene in rat liver and did not change in response to PH treatment [cycle threshold (Ct), control, 21.8 ± 0.2; PH, 22 ± 0.3]. Fold induction values were calculated by subtracting the mean difference of gene and GAPDH Ct number for each treatment group from the mean difference of gene and GAPDH Ct number for the vehicle group and raising this difference to the power of 2.

Statistical analyses were performed using a two-tailed Student's t test at α = 0.01 level of significance.

Results and Discussion

As expected from the literature (Vargas et al., 1998; Lamb and Franklin, 2000), significant increases in the amount of mRNA for UGT1A6 (20-fold) and, to a lesser extent, UGT2B1 (4-fold) and QR (5-fold) were detected in rat liver in response to PH treatment of 150 mg/kg/day (Fig. 1). The mRNA levels of UGT1A1 were not affected substantially (<2-fold) by this treatment. Similar increases in UGT1A6 (17-fold), UGT2B1 (3-fold), GST (6-fold), and QR (11-fold) mRNA were observed in liver after PH treatment of rats at 75 mg/kg/day for 3 days (Table 2). These results were similar to those reported by Vargas et al. (1998). The observed lack of dose proportionality in the increase of the mRNA of these enzymes between 75 and 150 mg/kg of PH needs further investigation to establish the time-dependence of the induction.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Comparison of constitutive (gray) and 1,7-phenanthroline-inducible (75 mg/kg/day for 3 days; black) expression of hepatic (A) and renal (B) drug-metabolizing enzymes and xenobiotic transporters.

Three animals were in each group; three determinations were performed for each animal. Some of the gene expression levels in log scale are shown in the box on the right in the figure.

View this table:
  • View inline
  • View popup
TABLE 2

Effects of 1,7-phenanthroline (75 mg/kg/day and 150 mg/kg/day, 3 days) on hepatic and kidney gene expression in male Sprague-Dawley rats

Data represent mean ± S.D.; n = 5 for the 150 mg/kg treatment group and n = 3 for the 75 mg/kg group. Three determinations were performed for each animal. Statistically significant differences between treated and control groups were evaluated by the Student's t test.

The transcription factor Nrf2 has been shown to be important for the induction of phase II enzymes. Induction of QR and UGT1A6 by oltipraz was observed in the wild-type, but not nrf2-deficient mice, which suggested that Nrf2 plays a major role in the regulation of these genes (Kwak et al., 2001b). Given that PH causes induction of a battery of genes similar to that of oltipraz, further studies are needed to elucidate the role of Nrf2, if any, in the inductive effects of PH.

PH caused a 3- to 4-fold induction of CYP3A1 gene expression in both liver and kidney; however, this is considered minor in comparison to the induction of CYP3A1 gene expression by pregnane X receptor agonists (∼30-fold) (Hartley and Klaassen, 2000) and may not be associated with increased protein levels (Dong et al., 1999). Significant decreases in the mRNA levels of CYP2C11 (17% of control) and Oatp2 (50% of control) were observed by PH treatment at 150 mg/kg/day. Down-regulation of CYP2C11 and Oatp2 by some aryl hydrocarbon receptor agonists, such as 3-methylcholanthrene, has been reported previously (Lee and Riddick, 2000; Rausch-Derra et al., 2001; Guo et al., 2002). However, PH does not induce CYP1A2 activity (Dong et al., 1999), suggesting that aryl hydrocarbon receptor may not be involved in the PH down-regulation of CYP2C11 and Oatp2.

In addition to the increases in QR and UGT mRNA levels, which are consistent with the previous report (Vargas et al., 1998), we also demonstrated that PH markedly increased hepatic Mrp3 mRNA levels (35-fold at 150 mg/kg and 99-fold at 75 mg/kg), but Mrp2 levels remained unaffected. Mrp3 is located on the basolateral membrane of polarized cells, and it plays a role in the hepatic elimination by transporting organic anions from liver to blood, which could lead to increased levels of xenobiotics and their metabolites in plasma and possibly an increase in urinary excretion (Konig et al., 1999; Kool et al., 1999). In normal rat liver, constitutive expression of Mrp3 mRNA is very low; however, the inducible nature of Mrp3 is well documented (Ogawa et al., 2000; Cherrington et al., 2002). Mrp3 has been shown to be induced by activators of the constitutive androstane receptor and an antioxidant/electrophile responsive element (Cherrington et al., 2002). However, a recent report by Xiong et al. (2002b) suggests that Mrp3 regulation occurs independent of constitutive androstane receptor.

In contrast to the robust increase in gene expression levels for UGT1A6 and Mrp3 in liver of PH-treated rats, there were much smaller changes in these genes in kidney by PH treatment at 75 mg/kg for 3 days (Table 2). The lack of evidence for a robust renal induction of xenobiotic transporters in rats treated with known hepatic enzyme inducers has been reported previously (Brady et al., 2002; Cherrington et al., 2002). In addition, previous studies have shown minimal inductive effects on drug-metabolizing genes by PH in the small intestine (Vargas et al., 1998).

Thus, PH is a pleiotropic inducer of genes responsible for drug metabolism and transport. These results indicate that in vivo data from PH-induced rats should be interpreted with caution, since up-regulation of Mrp3 gene expression may result in increased efflux of glucuronides and other xenobiotics from liver into the plasma compartment (Gregus et al., 1990; Xiong et al., 2002a). Further studies are needed to investigate the mechanism by which PH induces Mrp3 and phase II enzymes, and to determine whether these changes in mRNA levels will correlate with protein levels and/or activity.

Footnotes

  • ↵ 1 Abbreviations used are: Mrp, multidrug resistance protein; Oatp, organic anion transporting polypeptide; PH, 1,7-phenanthroline; GST, glutathione S-transferase; UGT, UDP-glucuronosyltransferase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Ct, cycle threshold; QR, quinone reductase; Nrf2, nuclear factor-erythroid 2-related factor.

    • Received December 10, 2002.
    • Accepted March 12, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    Borst P, Evers R, Kool M, and Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, and Klaassen CD (2002) Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30: 838-844.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Buetler TM, Gallagher EP, Wang C, Stahl DL, Hayes JD, and Eaton DL (1995) Induction of phase I and II drug-metabolizing enzyme mRNA, protein and activity by BHA, ethoxyquin and oltipraz. Toxicol Appl Pharmacol 135: 45-57.
    OpenUrlCrossRefPubMed
  4. ↵
    Cherrington NJ, Hartley DP, Li N, Johnson DR, and Klaassen CD (2002) Organ distribution of multidrug resistance protein 1, 2 and 3 (Mrp1, 2 and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300: 97-104.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Dong JQ, Etheridge AS, and Smith PC (1999) Effect of selective phase II enzyme inducers on glucuronidation of benoxaprofen in rats. Drug Metab Dispos 27: 1423-1428.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Franklin MR and Moody DE (1992) Concomitant induction of microsomal epoxide hydrolase and UDP-glucuronosyltransferase activities by dipyridine compounds. Drug Metab Dispos 20: 26-729.
    OpenUrl
  7. ↵
    Franklin MR, Slawson MH, and Moody DE (1993) Selective induction of rat liver phase II enzymes by N-heterocycle analogues of phenanthrene: a response exhibiting high correlation between UDP-glucuronosyltransferase and microsomal epoxide hydrolase activities. Xenobiotica 23: 267-277.
    OpenUrlPubMed
  8. ↵
    Gregus Z, Madhu C, and Klaassen CD (1990) Effect of microsomal enzyme inducers on biliary and urinary excretion of acetaminophen metabolites in rats. Drug Metab Dispos 18: 10-19.
    OpenUrlAbstract
  9. ↵
    Guo GL, Choudhuri S, and Klaassen CD (2002) Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways. J Pharmacol Exp Ther 300: 206-212.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Hartley DP and Klaassen CD (2000) Detection of chemical-induced differential expression of rat hepatic cytochrome P450 mRNA transcripts using branched DNA signal amplification technology. Drug Metab Dispos 28: 608-616.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Hirohashi T, Suzuki H, and Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274: 15181-15185.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Konig J, Rost D, Cui Y, and Keppler D (1999) Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29: 1156-1163.
    OpenUrlCrossRefPubMed
  13. ↵
    Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, et al. (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96: 6914-6919.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, Yamamoto M, and Kensler TW (2001a) Role of phase 2 enzyme induction in chemoprotection by dithiolthiones. Mutat Res 480–481: 305-315.
    OpenUrlCrossRefPubMed
  15. ↵
    Kwak MK, Itoh K, Yamamoto M, Sutter TR, and Kensler TW (2001b) Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent 3H-1,2-dimethiole-2-thione. Mol Med 7: 135-145.
    OpenUrlPubMed
  16. ↵
    Lamb JG and Franklin MR (2000) Early events in the induction of rat hepatic UDP-glucuronosyltransferases, glutathione S-transferase, and microsomal epoxide hydrolase by 1,7-phenanthroline: comparison with oltipraz, tert-butyl-4-hydroxyanisole and tert-butylhydroquinone. Drug Metab Dispos 28: 1018-1023.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Lee C and Riddick DS (2000) Transcriptional suppression of cytochrome P450 2C11 gene expression by 3-methylcholanthrene. Biochem Pharmacol 59: 1417-1423.
    OpenUrlCrossRefPubMed
  18. ↵
    Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, and Sugiyama Y (2000) Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 278: G438-G446.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Rausch-Derra LC, Hartley DP, Meier PJ, and Klaassen CD (2001) Differential effects of microsomal enzyme-inducing chemicals on the hepatic expression of rat organic anion transporters, OATP1 and OATP2. Hepatology 33: 1469-1478.
    OpenUrlCrossRefPubMed
  20. ↵
    Vargas M, Lamb JG, and Franklin MR (1998) Phase II-selective induction of hepatic drug-metabolizing enzymes by oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione], 1,7-phenanthroline and 2,2′-dipyridyl in rats is not accompanied by induction of intestinal enzymes. Drug Metab Dispos 26: 91-97.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, and Brouwer KLM (2002a) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment of phenobarbital pretreatment. Drug Metab Dispos 30: 962-969.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Xiong H, Yoshinari K, Brouwer KLM, and Negishi M (2002b) Role of constitutive androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by phenobarbital. Drug Metab Dispos 30: 918-923.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 31 (6)
Drug Metabolism and Disposition
Vol. 31, Issue 6
1 Jun 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
INDUCTION OF HEPATIC PHASE II DRUG-METABOLIZING ENZYMES BY 1,7-PHENANTHROLINE IN RATS IS ACCOMPANIED BY INDUCTION OF MRP3
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

INDUCTION OF HEPATIC PHASE II DRUG-METABOLIZING ENZYMES BY 1,7-PHENANTHROLINE IN RATS IS ACCOMPANIED BY INDUCTION OF MRP3

Sui Wang, Dylan P. Hartley, Suzanne L. Ciccotto, Stella H. Vincent, Ronald B. Franklin and Mi-Sook Kim
Drug Metabolism and Disposition June 1, 2003, 31 (6) 773-775; DOI: https://doi.org/10.1124/dmd.31.6.773

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

INDUCTION OF HEPATIC PHASE II DRUG-METABOLIZING ENZYMES BY 1,7-PHENANTHROLINE IN RATS IS ACCOMPANIED BY INDUCTION OF MRP3

Sui Wang, Dylan P. Hartley, Suzanne L. Ciccotto, Stella H. Vincent, Ronald B. Franklin and Mi-Sook Kim
Drug Metabolism and Disposition June 1, 2003, 31 (6) 773-775; DOI: https://doi.org/10.1124/dmd.31.6.773
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Role of Human MSRA on Sulindac Activation
  • Determination of Acyl-, O-, and N-Glucuronide
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics